Galecto, Inc. (GLTO) DCF Valuation

Avaliação DCF Galecto, Inc. (GLTO)

US | Healthcare | Biotechnology | NASDAQ
Galecto, Inc. (GLTO) DCF Valuation

Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas

Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria

Pré-Construídos Para Uso Rápido E Eficiente

Compatível com MAC/PC, totalmente desbloqueado

Não É Necessária Experiência; Fácil De Seguir

Galecto, Inc. (GLTO) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

O valor verdadeiro da Discover Galecto, Inc. com nossa calculadora DCF de nível profissional! Ajuste as principais suposições, explore vários cenários e avalie como as mudanças afetam a avaliação da Galecto, Inc. - tudo dentro de um único modelo do Excel.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -34.6 -51.3 -61.1 -37.5 -22.3 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .2 .4 .5 .8 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -34.8 -51.8 -61.6 -38.3 -22.3 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 163.6 100.2 60.2 33.2 14.2 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 2.2 2.3 1.4 1.7 .0
Account Receivables, % 100 100 100 100 100
Inventories 3.3 7.3 2.3 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 2.9 1.5 3.4 1.7 .4 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 -.2 -.2 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.19161 -0.19161 -0.19161 -0.19161 -0.19161 -0.19161 -0.19161 -0.19161 -0.19161 -0.19161
EBITAT -36.0 -51.3 -62.0 -38.3 -22.3 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -38.5 -56.5 -54.0 -37.3 -21.9 -.4 .0 .0 .0 .0
WACC, % 10.05 10.04 10.05 10.05 10.05 10.05 10.05 10.05 10.05 10.05
PV UFCF
SUM PV UFCF -.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -14
Equity Value 14
Diluted Shares Outstanding, MM 1
Equity Value Per Share 11.89

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real GLTO financials.
  • Real-World Data: Historical data and forward-looking estimates (as illustrated in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the effects of your inputs on Galecto, Inc.'s valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Customizable Financial Metrics: Adjust key inputs such as revenue projections, operating margins, and research expenditures.
  • Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and additional financial outputs.
  • High-Precision Accuracy: Leverages Galecto’s actual financial data for dependable valuation results.
  • Streamlined Scenario Testing: Easily explore various assumptions and evaluate different outcomes.
  • Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Galecto, Inc.'s (GLTO) preloaded data.
  • 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
  • 3. Observe Results Instantly: The DCF model automatically calculates intrinsic value and NPV for Galecto, Inc. (GLTO).
  • 4. Evaluate Scenarios: Analyze different valuation outcomes by comparing multiple forecasts.
  • 5. Present with Assurance: Deliver professional valuation insights to bolster your decision-making for Galecto, Inc. (GLTO).

Why Choose This Calculator for Galecto, Inc. (GLTO)?

  • Accurate Data: Up-to-date Galecto financials provide dependable valuation results.
  • Customizable: Tailor key inputs such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-structured calculations save you the hassle of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants focused on Galecto, Inc. (GLTO).
  • User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.

Who Should Use This Product?

  • Individual Investors: Gain insights to make educated decisions on buying or selling Galecto, Inc. (GLTO) stock.
  • Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for Galecto, Inc. (GLTO).
  • Consultants: Provide clients with accurate valuation assessments for Galecto, Inc. (GLTO) efficiently.
  • Business Owners: Learn about the valuation methods of biotech companies like Galecto, Inc. (GLTO) to inform your own business strategies.
  • Finance Students: Explore real-world data and scenarios to master valuation techniques relevant to Galecto, Inc. (GLTO).

What the Template Contains

  • Pre-Filled Data: Includes Galecto, Inc.'s (GLTO) historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Galecto, Inc.'s (GLTO) profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.

No products were found matching.